Literature DB >> 29933437

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.

Jennifer A Fulcher1,2, Yushen Du3, Tian-Hao Zhang3, Ren Sun3, Raphael J Landovitz1,4.   

Abstract

Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29933437      PMCID： PMC6093998          DOI： 10.1093/cid/ciy228

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

1.  Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

Review 2.  The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Authors:  Natalia Stella-Ascariz; José Ramón Arribas; Roger Paredes; Jonathan Z Li
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

3.  Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients.

Authors:  Kirsten White; Rima Kulkarni; Michael D Miller
Journal:  J Antimicrob Chemother       Date:  2015-06-24       Impact factor: 5.790

4.  ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Authors:  Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

5.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Authors:  Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min
Journal:  Lancet       Date:  2013-07-03       Impact factor: 79.321

6.  Emergent drug resistance with integrase strand transfer inhibitor-based regimens.

Authors:  Katherine J Lepik; P Richard Harrigan; Benita Yip; Lu Wang; Marjorie A Robbins; Wendy W Zhang; Junine Toy; Linda Akagi; Viviane D Lima; Silvia Guillemi; Julio S G Montaner; Rolando Barrios
Journal:  AIDS       Date:  2017-06-19       Impact factor: 4.177

7.  Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?

Authors:  Yiannis Koullias; Paul E Sax; Naomi F Fields; Rochelle P Walensky; Emily P Hyle
Journal:  Clin Infect Dis       Date:  2017-10-15       Impact factor: 9.079

8.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Authors:  Bonaventura Clotet; Judith Feinberg; Jan van Lunzen; Marie-Aude Khuong-Josses; Andrea Antinori; Irina Dumitru; Vadim Pokrovskiy; Jan Fehr; Roberto Ortiz; Michael Saag; Julia Harris; Clare Brennan; Tamio Fujiwara; Sherene Min
Journal:  Lancet       Date:  2014-04-01       Impact factor: 79.321

9.  Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Authors:  Mark A Winters; Robert M Lloyd; Robert W Shafer; Michael J Kozal; Michael D Miller; Mark Holodniy
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

10.  Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Authors:  Tomas Doyle; David T Dunn; Francesca Ceccherini-Silberstein; Carmen De Mendoza; Frederico Garcia; Erasmus Smit; Esther Fearnhill; Anne-Genevieve Marcelin; Javier Martinez-Picado; Rolf Kaiser; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2015-08-26       Impact factor: 5.790
View more
  10 in total

1.  Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy.

Authors:  Kairoonisha Mahomed; Carole L Wallis; Liezl Dunn; Shavani Maharaj; Gary Maartens; Graeme Meintjes
Journal:  South Afr J HIV Med       Date:  2020-07-02       Impact factor: 2.744

2.  Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.

Authors:  Dawit Assefa Arimide; Zsófia Ilona Szojka; Kidist Zealiyas; Atsbeha Gebreegziabxier; Fekadu Adugna; Sviataslau Sasinovich; Per Björkman; Patrik Medstrand
Journal:  Viruses       Date:  2022-03-30       Impact factor: 5.818

3.  Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis.

Authors:  Kimia Kamelian; Katherine J Lepik; William Chau; Benita Yip; Wendy W Zhang; Viviane Dias Lima; Marjorie A Robbins; Conan Woods; Andrea Olmstead; Jeffrey B Joy; Rolando Barrios; P Richard Harrigan
Journal:  Open Forum Infect Dis       Date:  2019-02-12       Impact factor: 3.835

4.  A systematic review of the genetic mechanisms of dolutegravir resistance.

Authors:  Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

5.  Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.

Authors:  Dominique L Braun; Thomas Scheier; Ulrich Ledermann; Markus Flepp; Karin J Metzner; Jürg Böni; Huldrych F Günthard
Journal:  Viruses       Date:  2020-11-19       Impact factor: 5.048

Review 6.  Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.

Authors:  Steven J Smith; Xue Zhi Zhao; Dario Oliveira Passos; Dmitry Lyumkis; Terrence R Burke; Stephen H Hughes
Journal:  Viruses       Date:  2021-01-29       Impact factor: 5.048

7.  Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.

Authors:  Rima K Acosta; Michelle L D'Antoni; Andrew Mulato; Stephen R Yant; Tomas Cihlar; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2022-04-07       Impact factor: 5.938

8.  Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naïve individual case report.

Authors:  Smitha Gudipati; Indira Brar; Alicia Golembieski; Zachary Hanna; Norman Markowitz
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

9.  Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study.

Authors:  Lucas E Hermans; Sergio Carmona; Monique Nijhuis; Hugo A Tempelman; Douglas D Richman; Michelle Moorhouse; Diederick E Grobbee; Willem D F Venter; Annemarie M J Wensing
Journal:  PLoS Med       Date:  2020-02-25       Impact factor: 11.069

10.  SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression.

Authors:  Hortensia Álvarez; Ezequiel Ruiz-Mateos; Pedro Miguel Juiz-González; Joana Vitallé; Irene Viéitez; María Del Carmen Vázquez-Friol; Isabel Torres-Beceiro; Alberto Pérez-Gómez; Pilar Gallego-García; Nuria Estévez-Gómez; Loretta De Chiara; Eva Poveda; David Posada; Josep M Llibre
Journal:  Microorganisms       Date:  2022-01-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.